Compare GTY & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | NNNN |
|---|---|---|
| Founded | 1955 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | GTY | NNNN |
|---|---|---|
| Price | $28.28 | $35.22 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $31.80 | N/A |
| AVG Volume (30 Days) | ★ 462.5K | 33.9K |
| Earning Date | 02-11-2026 | 04-28-2026 |
| Dividend Yield | ★ 6.86% | N/A |
| EPS Growth | ★ 10.25 | N/A |
| EPS | ★ 1.28 | 0.06 |
| Revenue | ★ $214,194,000.00 | $6,920,153.00 |
| Revenue This Year | $6.48 | N/A |
| Revenue Next Year | $8.92 | N/A |
| P/E Ratio | ★ $22.13 | $553.82 |
| Revenue Growth | ★ 8.17 | N/A |
| 52 Week Low | $25.39 | $5.18 |
| 52 Week High | $32.17 | $55.65 |
| Indicator | GTY | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 54.20 |
| Support Level | $27.08 | $30.15 |
| Resistance Level | $28.77 | $35.40 |
| Average True Range (ATR) | 0.47 | 3.55 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 69.83 | 57.12 |
Getty Realty Corp is the real estate investment trust in the U.S. specializing in the acquisition, financing, and development of convenience, automotive, and other single tenant retail real estate. The company's portfolio includes convenience stores, car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, collision), automotive parts retailers, and certain other freestanding retail properties, including drive-thru quick service restaurants. It generates majority of the revenue in the form of rental income.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.